Health Care [ 6/12 ] | Biotechnology [ 32/73 ]
NASDAQ | Common Stock
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma.
The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial.
In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector.
The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 16, 25 | 0.89 Increased by +297.78% | -0.07 Increased by +1.37 K% |
| Mar 19, 25 | -0.41 Increased by +36.92% | -0.41 Increased by +1.20% |
| Nov 5, 24 | -0.37 Increased by +32.73% | -0.45 Increased by +17.91% |
| Aug 8, 24 | -0.38 Increased by +32.14% | -0.45 Increased by +15.56% |
| May 9, 24 | -0.45 Increased by +15.09% | -0.50 Increased by +10.00% |
| Mar 14, 24 | -0.65 Increased by +71.37% | -0.55 Decreased by -18.18% |
| Nov 9, 23 | -0.55 Decreased by -3.77% | -0.51 Decreased by -7.84% |
| Aug 9, 23 | -0.56 Decreased by -3.70% | -0.54 Decreased by -3.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 109.16 M Increased by +12.67 K% | 76.56 M Increased by +372.82% | Increased by +70.13% Increased by +102.14% |
| Dec 31, 24 | 4.17 M Increased by +1.46 K% | -36.07 M Increased by +8.44% | Decreased by -864.44% Increased by +94.12% |
| Sep 30, 24 | 791.00 K Increased by +434.46% | -31.23 M Increased by +4.57% | Decreased by -3.95 K% Increased by +82.14% |
| Jun 30, 24 | 771.00 K Increased by +678.79% | -31.21 M Increased by +6.26% | Decreased by -4.05 K% Increased by +87.96% |
| Mar 31, 24 | 855.00 K Decreased by -50.29% | -28.06 M Increased by +10.24% | Decreased by -3.28 K% Decreased by -80.57% |
| Dec 31, 23 | 268.00 K Decreased by -48.56% | -39.40 M Decreased by -24.35% | Decreased by -14.70 K% Decreased by -141.75% |
| Sep 30, 23 | 148.00 K Decreased by -93.35% | -32.72 M Decreased by -6.41% | Decreased by -22.11 K% Decreased by -1.50 K% |
| Jun 30, 23 | 99.00 K Decreased by -92.91% | -33.29 M Decreased by -7.43% | Decreased by -33.63 K% Decreased by -1.41 K% |